Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules
Overview
Among the causes of the solitary pulmonary nodule (SPN), benign causes including tuberculosis was noted on 15 to 60 percents in various studies. Although the characteristics of chest imaging is helpful in diagnosis and percutaneous needle biopsy for pulmonary nodule has been represented high diagnostic yield in many reports, but still surgical biopsy has been needed in definite diagnosis of pulmonary nodules in many cases. The aim of this study is to evaluate the usefulness of interferon-gamma release assay in addition to the percutaneous needle biopsy, in diagnosis of pulmonary nodules.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 2010
Detailed Description
Among the patients who failed to diagnosis by percutaneous needle biopsy and needed to have Surgical biopsy, thirty percents of the patients were diagnosed as benign nodules and about six percents were diagnosed as tuberculosis in Seoul National University Hospital during 2007-2008. The investigators want to know whether conducting an interferon-gamma release assay in addition to percutaneous needle biopsy is helpful in diagnosis of lung nodules.
Arms, Groups and Cohorts
- IGRA in solitary pulmonary nodules
- Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
Clinical Trial Outcome Measures
Primary Measures
- Positive rate of the interferon-gamma release assay
- Time Frame: within 36hrs after blood sampling
- the result of the interferon-gamma release assay is reported in three different categories as positive, negative or indeterminate. We want to know whether the positive rate of the interferon-gamma release asssay would be significantly different according to the pathologic diagnosis of lung nodules confirmed by percutaneous needle biopsy.
Secondary Measures
- Positive rate of the Tuberculin skin test
- Time Frame: 48hours after tuberculin skin test
- We will conduct Tuberculin skin test and evaluate the whether the positive rate of the Tuberculin skin test would be different according to the pathologic diagnosis of lung nodules confirmed by percutaneous needle biopsy.
Participating in This Clinical Trial
Inclusion Criteria
- Age> 18 years – in patients with solitary pulmonary nodule – who had percutaneous needle biopsy for diagnosis of lung nodule Exclusion Criteria:
- patients who do not agree the study enrollment
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Seoul National University Hospital
- Provider of Information About this Clinical Study
- Young Whan Kim/professor, Seoul National University Hospital
- Overall Contact(s)
- Young Whan Kim, MD, 82-2-2072-2856, ywkim@snu.ac.kr
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.